- Home
- BANX vs FBRX Comparison
BANX vs FBRX Comparison
Compare BANX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- FBRX
- Stock Information
- Founded
- BANX 2013
- FBRX N/A
- Country
- BANX United States
- FBRX United States
- Employees
- BANX N/A
- FBRX N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- BANX Finance
- FBRX Health Care
- Exchange
- BANX Nasdaq
- FBRX Nasdaq
- Market Cap
- BANX 146.9M
- FBRX 154.5M
- IPO Year
- BANX N/A
- FBRX N/A
- Fundamental
- Price
- BANX $22.14
- FBRX $13.21
- Analyst Decision
- BANX
- FBRX Strong Buy
- Analyst Count
- BANX 0
- FBRX 3
- Target Price
- BANX N/A
- FBRX $68.00
- AVG Volume (30 Days)
- BANX 23.4K
- FBRX 81.5K
- Earning Date
- BANX 06-17-2025
- FBRX 11-13-2025
- Dividend Yield
- BANX 9.66%
- FBRX N/A
- EPS Growth
- BANX N/A
- FBRX N/A
- EPS
- BANX 2.35
- FBRX N/A
- Revenue
- BANX $29,467,794.00
- FBRX N/A
- Revenue This Year
- BANX N/A
- FBRX N/A
- Revenue Next Year
- BANX N/A
- FBRX N/A
- P/E Ratio
- BANX $8.88
- FBRX N/A
- Revenue Growth
- BANX 2.73
- FBRX N/A
- 52 Week Low
- BANX $17.99
- FBRX $4.11
- 52 Week High
- BANX $21.67
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- BANX 76.71
- FBRX 68.54
- Support Level
- BANX $21.17
- FBRX $10.11
- Resistance Level
- BANX $22.38
- FBRX $11.57
- Average True Range (ATR)
- BANX 0.28
- FBRX 0.93
- MACD
- BANX 0.12
- FBRX 0.18
- Stochastic Oscillator
- BANX 87.23
- FBRX 94.76
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).